News & Blog

News & Blog

  • Reset
News | Jan 9 2023

Prime Medicine announces recent progress and highlights 2023 strategic priorities

New preclinical data in Friedrich’s ataxia and cystic fibrosis provided further proof-of-concept for Prime Editing’s ability to achieve ...

Industry News
News | Jan 4 2023

Hereditary Ataxias Added as Eligible Condition for CDMRP Funding!

Advocacy
News | Dec 7 2022

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

Industry News
News | Jun 1 2022

Strong Partnership Funds the 2022 Ataxian Athlete Initiative (AAI) for People with Ataxia

News | Mar 30 2022

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia

Industry News
News | Mar 28 2022

Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich’s Ataxia

Industry News
News | Feb 28 2022

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

Industry News
News | Feb 16 2022

Lexeo Announces FDA Clearance of IND Application for LX2006 for Friedreich’s Ataxia Cardiomyopathy

Industry News
News | Feb 14 2022

Larimar Therapeutics Provides Update on CTI-1601 Clinical Program

Industry News
News | Aug 12 2021

Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results

Industry News
News | Aug 9 2021

Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results

Industry News
News | Jun 30 2021

Lexeo Therapeutics Receives Rare Pediatric Disease & Orphan Drug Designations for LX2006

Industry News